Stay updated on Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page
- Check6 days agoChange DetectedThe page has been updated to reflect a new version of the HHS Vulnerability Disclosure, changing from v2.16.6 to v2.16.8.SummaryDifference0.2%
- Check13 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.1%
- Check20 days agoChange DetectedA service alert has been added indicating planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference1%
- Check27 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant piece of information regarding the modernization of ClinicalTrials.gov data ingest has been deleted.SummaryDifference1%
- Check34 days agoNo Change Detected
- Check42 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.9%
- Check56 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
Stay in the know with updates to Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Ruxolitinib in Hodgkin Lymphoma Clinical Trial page.